
Caribou Biosciences (CRBU) Stock Forecast & Price Target
Caribou Biosciences (CRBU) Analyst Ratings
Bulls say
Caribou Biosciences is a promising biopharmaceutical company driven by its transformative and innovative approach to developing therapies for patients with hematologic malignancies. Its strong focus on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates and its successful operations in the United States, where it derives the majority of its revenue, highlight its potential for growth and success. Despite some impairment charges reported in its financials, the company remains financially stable and constantly strives to expand its capabilities and reach, which solidifies its positive outlook for the future.
Bears say
Caribou Biosciences is facing potential risks and challenges due to upcoming catalysts, such as longer follow-up data from the ANTLER trial and initial data for CB-011. These risks, combined with our DCF-based valuation and probability of approval assumptions, lead us to have a skeptical outlook on the stock. Additionally, potential risks such as negative clinical results, delays in advancing candidates, and competitive landscape risks could also negatively impact the company's future success.
This aggregate rating is based on analysts' research of Caribou Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Caribou Biosciences (CRBU) Analyst Forecast & Price Prediction
Start investing in Caribou Biosciences (CRBU)
Order type
Buy in
Order amount
Est. shares
0 shares